<?xml version="1.0" encoding="UTF-8"?>
<p>Many pharmaceutical firms have come forward to develop a vaccine against COVID-19. CureVac, TÃ¼bingen, Germany and Inovio Pharmaceuticals Inc., Plymouth Meeting, Pennsylvania, USA/Beijing Advaccine Biotechnology Co., Beijing, China with funding from the Coalition for Epidemic Preparedness Innovations (CEPI) is working on separate nucleic acid vaccines [
 <xref rid="B48-biology-09-00141" ref-type="bibr">48</xref>]. Janssen (Johnson &amp; Johnson), Beerse, Belgium and Codagenix Inc., Farmingdale NY, USA/Serum Institute of India, Pune, India in collaboration with the University of Queensland, are working towards developing whole virus vaccines, whereas CEPI, Davos, Switzerland; Novavax, MD, USA; Clover Biopharmaceuticals, Chengdu, China; Vaxart Inc, San Francisco, CA, United States and Sanofi Pharmaceuticals, Paris, France are in efforts to develop vaccines using recombinant proteins for COVID-19 [
 <xref rid="B26-biology-09-00141" ref-type="bibr">26</xref>,
 <xref rid="B52-biology-09-00141" ref-type="bibr">52</xref>].
</p>
